zimmytws
Biotechs such as Gilead (NASDAQ:GILD) and Vertex Pharma (NASDAQ:VRTX), with a high local tax bill, a heavy U.S.-based manufacturing footprint, and an IP rights portfolio, look somewhat insulated from potential pharma tariffs, The Wall Street Journal said in a recent report.